BioSpace News Archive

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the opening of its R&D operations at the Cheyney University science center located in Chester County, PA.

Following extensive support of, and collaboration with, public health professionals in China, Oxford Nanopore has shipped an additional 200 MinION sequencers and related consumables to China.

Brightree announced today it has agreed to acquire privately held SnapWorx, LLC, a market-leading software company providing patient contact management and workflow optimization for the continuous positive airway pressure (CPAP) resupply market.

First projects announced under the Dementia Community Investment funding program

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today that it has received a letter from The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement

In a New York Times article today about patients and medication errors, pharmacists describe being stressed about workplace conditions that may lead to mistakes impacting patient safety.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approved an inducement award consisting of a stock option to purchase up to 156,000 shares of the Company’s common stock to David E. Strauss.

COPAN announces a kit that pairs 3mL of UTM® universal viral transport medium and two FLOQSwabs™: one minitip and one regular flocked swab

SGI-DNA, creators of the BioXp™ 3200 System and Gibson Assembly® Reagents, has launched Vmax™ X2 Competent Cells, designed to generate two to four times more soluble protein in half of the time of current methods reliant on E. coli.

VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced today that the Company will participate in several industry events in the coming months.